Evidence map›Paper›PMID 28324469›Full record

ReviewCurrent cardiology reports2017

Stem Cells in Cardiovascular Medicine: the Road to Regenerative Therapies.

Christopher W Anderson, Nicole Boardman, Jiesi Luo, Jinkyu Park, Yibing Qyang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current cardiology reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Christopher W AndersonVascular Biology and Therapeutics Program, Yale University, New Haven, CT, 06510, USA.
Nicole BoardmanVascular Biology and Therapeutics Program, Yale University, New Haven, CT, 06510, USA.
Jiesi LuoVascular Biology and Therapeutics Program, Yale University, New Haven, CT, 06510, USA.
Jinkyu ParkVascular Biology and Therapeutics Program, Yale University, New Haven, CT, 06510, USA.
Yibing QyangVascular Biology and Therapeutics Program, Yale University, New Haven, CT, 06510, USA. yibing.qyang@yale.edu.

Funding

Human tissue-engineered blood vessels using induced pluripotent stem cellsR01HL116705 · NHLBI · YALE UNIVERSITY · PI QYANG, YIBING · 2013 to 2017
$2.0M
Biomechanical Signaling in Human Familial Hypertrophic CardiomyopathyR01HL131940 · NHLBI · YALE UNIVERSITY · PI QYANG, YIBING · 2016 to 2019
$1.7M
Derivation of Heart Cells from Human Embryonic and Induced Pluripotent Stem CellsK02HL101990 · NHLBI · YALE UNIVERSITY · PI QYANG, YIBING · 2010 to 2014
$489k
NHLBI NIH HHS K02 HL101990NHLBI NIH HHS R01 HL116705NHLBI NIH HHS R01 HL131940
6 · The paper itself

Abstract

purpose of reviewThe purpose of this review is to provide a broad overview of current trends in stem cell research and its applications in cardiovascular medicine. Researches on different stem cell sources, their inherent characteristics, and the limitations they have in medical applications are discussed. Additionally, uses of stem cells for both modeling and treating cardiovascular disease are discussed, taking note of the obstacles these engineered interventions must overcome to be clinically viable. RECENT

findingsTissue engineering aims to replace dysfunctional tissues with engineered constructs. Stem cell technologies have been a great enabling factor in working toward this goal. Many tissue-engineered products are in development that utilize stem cell technology. Although promising, some refinement must be made to these constructs with respect to safety and functionality. A deeper understanding of basic differentiation and tissue developmental mechanisms is required to allow these engineered tissues to be translated into the clinic.

Indexed as

RegenerationStem CellsTissue EngineeringCardiovascular DiseasesCell DifferentiationHumansCardiovascularEmbryonic stem cellsInduced pluripotent stem cellsRegenerative medicineStem cellsTissue engineering

Identifiers

PMID28324469
PMCPMC5518932

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.